Hesingue, France

Olivier Rogel

USPTO Granted Patents = 13 

 

Average Co-Inventor Count = 7.3

ph-index = 3

Forward Citations = 45(Granted Patents)


Location History:

  • Basel, CH (2012 - 2014)
  • Hésingue, FR (2012 - 2015)
  • Hesingue, FR (2016 - 2017)

Company Filing History:


Years Active: 2012-2017

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: Innovator Spotlight: Olivier Rogel - Pioneering Science in Hesingue, FR

Introduction:

Olivier Rogel, a renowned inventor based in Hesingue, France, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 13 patents. His groundbreaking work focuses on developing novel compounds targeting matrix metalloproteases and complement pathway modulators for the treatment of various disorders and diseases.

Latest Patents:

Rogel's latest patents showcase his innovative approach to pharmaceutical research. One such patent revolves around arylsulfonamide-based matrix metalloprotease inhibitors. These compounds, inhibitors of MMP-2, MMP-8, MMP-9, MMP-12, and MMP-13, offer promising therapeutic potential for disorders characterized by abnormal MMP activity. Additionally, Rogel has patented complement pathway modulators, introducing a new compound (formula I) with therapeutic uses and manufacturing methods, paving the way for advanced treatment modalities.

Career Highlights:

Olivier Rogel is a key asset at Novartis AG, a leading pharmaceutical company at the forefront of cutting-edge research and development. His expertise and inventive spirit have led to numerous successful patent applications, cementing his reputation as a trailblazer in the pharmaceutical industry. Rogel's dedication to advancing medical science through innovation is evident in his patent portfolio, where each invention demonstrates a deep understanding of complex biological mechanisms.

Collaborations:

In his quest for scientific excellence, Olivier Rogel has collaborated with esteemed colleagues such as Ulrich Hommel and Edwige Liliane Jeanne Lorthiois. Together, they have synergized their expertise to push the boundaries of pharmaceutical innovation, working towards the shared goal of improving patient outcomes and advancing medical knowledge.

Conclusion:

In conclusion, Olivier Rogel stands as a beacon of ingenuity in the realm of pharmaceutical research. His inventive spirit, coupled with a strong dedication to scientific progress, has fueled the development of groundbreaking compounds with the potential to revolutionize therapeutic interventions. With a focus on matrix metalloprotease inhibitors and complement pathway modulators, Rogel's work exemplifies the transformative power of innovation in addressing complex medical challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…